r****5
发帖数: 618 | 1 After several years of downside, pharm section is coming up again. Among
them big pharm will have lower risk compared with small ones. Some of good
ones MRK, AMGN, PFE. Do your research before rush in. | p********o
发帖数: 8012 | | S********t
发帖数: 566 | | l**********6
发帖数: 52 | | k**********4
发帖数: 16092 | 5 it is possible , with the development of monoclonal drugs,
but u will never know unless you are the sugar daddy of
the ceo.
good
【在 r****5 的大作中提到】
: After several years of downside, pharm section is coming up again. Among
: them big pharm will have lower risk compared with small ones. Some of good
: ones MRK, AMGN, PFE. Do your research before rush in.
| r****5
发帖数: 618 | 6 The reason why I said big pharm not small ones. Any failure of clinical
trials does not influence the price too much. Instead, a combined portfolio
are key to those companies. So far, MRK/PFE should be the lead. JNJ/NVS
are good but their potential is also limited.
【在 k**********4 的大作中提到】
: it is possible , with the development of monoclonal drugs,
: but u will never know unless you are the sugar daddy of
: the ceo.
:
: good
| c*****r
发帖数: 439 | |
|
